<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SECOBARBITAL SODIUM <img border="0" src="../images/pr.gif"/></span><br/>(see-koe-bar'bi-tal)<br/><span class="topboxtradename">Seconal Sodium<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">sedative-hypnotic</span>; <span class="classification">barbiturate</span>; <span class="classification">anxiolytic</span><br/><b>Pregnancy Category: </b>D<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Short-acting barbiturate with CNS depressant effects as well as mood alteration from excitation to mild sedation, hypnosis,
         and deep coma. Depresses the sensory cortex, decreases motor activity, alters cerebellar function and produces drowsiness,
         sedation and hypnosis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Alters cerebellar function and produces drowsiness, sedation and hypnosis.</p>
<h1><a name="uses">Uses</a></h1>
<p>Hypnotic for simple insomnia and preoperatively to provide basal hypnosis for general, spinal, or regional anesthesia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of sensitivity to barbiturates; porphyria; severe liver function; severe respiratory disease; nephritic syndrome;
         pregnancy (category D), parturition, fetal immaturity; uncontrolled pain. Use of sterile injection containing polyethylene
         glycol vehicle in patients with renal insufficiency.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnant women with toxemia or history of bleeding; labor and delivery, lactation; liver or kidney function impairment, older
         adult, debilitated individuals; children.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Sedative</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100300 mg/d in 3 divided doses<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 46 mg/kg/d in 3 divided doses<br/><br/><span class="indicationtitle">Preoperative Sedative</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100300 mg 12 h before surgery<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 50100 mg 12 h before surgery<br/><br/><span class="indicationtitle">Hypnotic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100200 mg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give hypnotic dose only after patient retires for the evening.</li>
<li>Crush and mix with a fluid or with food if patient cannot swallow pill.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, lethargy, hangover, paradoxical excitement in the older adult patient. <span class="typehead">Respiratory:</span> <span class="speceff-life">Respiratory depression, laryngospasm</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Phenmetrazine</b> antagonizes effects of secobarbital; <span class="classification">cns depressants</span>, <b>alcohol,</b> <span class="classification">sedatives</span> compound CNS depression; <span class="classification">mao inhibitors</span> cause excessive CNS depression; <b>methoxyflurane</b> increases risk of nephrotoxicity. <span class="typehead">Herbal:</span> <b>Kava-kava,</b> <b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90% absorbed from GI tract. <span class="typehead">Onset:</span> 1530 min. <span class="typehead">Duration:</span> 14 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 30 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Be alert to unexpected responses and report promptly. Older adult or debilitated patients and children sometimes have paradoxical
            response to barbiturate therapy (i.e., irritability, marked excitement as inappropriate tearfulness and aggression in children,
            depression, and confusion). Protect older adult patients from falling, irrational behavior, and effects of depression (anorexia,
            social withdrawal).
         </li>
<li>Patient may become irritable, and uncooperative after a subhypnotic dose of a short-acting barbiturate (uncommon response).</li>
<li>Be aware that barbiturates do not have analgesic action, and may produce restlessness when given to patients in pain.</li>
<li>Long-term therapy may result in nutritional folate (B<sub>9</sub>) and vitamin D deficiency.
         </li>
<li>Lab tests: Obtain liver function and hematology tests, serum folate and vitamin D levels during prolonged therapy.</li>
<li>Observe closely for changes in established drug regimen effectiveness whenever a barbiturate is added, at least during early
            phase of barbiturate use. Barbiturates increase the metabolism of many drugs, leading to decreased pharmacologic effects of
            those drugs.
         </li>
<li>Be alert for acute toxicity (intoxication) characterized by profound CNS depression, respiratory depression that may progress
            to Cheyne-Stokes respirations, hypoventilation, cyanosis, cold clammy skin, hypothermia, constricted pupils (but may be dilated
            in severe intoxication), shock, oliguria, tachycardia, hypotension, respiration arrest, circulatory collapse, and death.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is established.</li>
<li>Store barbiturates in a safe place; not on the bedside table or other readily accessible places. It is possible to forget
            having taken the drug, and in half-wakened conditions take more and accidentally overdose.
         </li>
<li>Barbiturates are reportedly teratogenic. Do not become pregnant. Use or add barrier contraception if using hormonal contraceptives.</li>
<li>Report onset of fever, sore throat or mouth, malaise, easy bruising or bleeding, petechiae, jaundice, rash to physician during
            prolonged therapy.
         </li>
<li>Do not consume alcohol in any amount when taking a barbiturate. It may severely impair judgment and abilities.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>